Intellectual property
Stemedica has applied for 26 patents, among which 8 have been approved. These patents primarily seek protection for manufacturing processes and usage of stem cells and stem cell factors. The scalable stem cells production know-how owned by Stemedica is the key to creation of stem cell drugs.
Stemedica and its partners have published 15 research papers on high-impact journals since 2012.
PUBLICATIONS
i、Ivan Cheng, Robert E.Mayle, etc. Functional Assessment of The Acute Local and Distal Transplantation of Human Neural Stem Cells after Spinal Cord Injury. Spine J 2012; 12(11)：1040-4
ii、Alex Kharazi; Michael L Levy, etc. Chicken Embryonic Brain: An in vivo Model for Verifying Neural Stem Cell Potency. J. Neurosurg. 2013; 119(2)：512-9
iii、D Y Park;R E Mayle;R L Smith,etc. Combined Transplantation of Human Neuronal and Mesenchymal Stem Cells following Spinal Cord Injury. Global Spine J 2013; 3(1)：1-6
iv、Grigory Vertelov; Ludmila Kharazi, etc. High Targeted Migration of Human Mesenchymal Stem Cells Grown in Hypoxia is Associated with Enhanced Activation of RhoA. Stem Cell Res Ther 2013; 4(1)：5
v、Anita A Kelkar; Javed Butler, etc. Mechanisms Contributing to the Progression of Ischemic and Nonischemic Dilated Cardiomyopathy. J. Am. Coll. Cardiol. 2015; 66(18)：2038-2047
vi、Ivan Cheng; Michael Githens, etc. Local Versus Distal Transplantation of Human Neural Stem Cells following Chronic Spinal Cord Injury. Spine J 2016; 16(6)：764-9
vii、Stephen J Greene; Stephen E Epstein, etc. Rationale and Design of a Randomized Controlled Trial of Allogeneic Mesenchymal Stem Cells in Patients with Nonischemic Cardiomyopathy. J Cardiovasc Med (Hagerstown) 2017; 18(4)：283-290
viii、Mihai Gheorghiade, Christopher J. Larson, etc. Developing New Treatments for Heart Failure Focus on the Heart. Circ Heart Fail. 2016 May;9(5).
ix、Dror Luger; Michael J Lipinski, etc. Intravenously-delivered Mesenchymal Stem Cells: Systemic Anti-inflammatory Effects Improve Left Ventricular Dysfunction in Acute Myocardial Infarction and Ischemic Cardiomyopathy. Circ. Res. 2017; 120(10)：1598-1613
x、Grigory Vertelov; Edgar Gutierrez, etc. Rigidity of Silicone Substrates controls cell Spreading and Stem Cell Differentiation. Sci. Rep. 2016; 6：33411
xi、Taoufiq Harach; Fabien Jammes, etc. Administrations of Human Adult Ischemia-Tolerant Mesenchymal Stem Cells and Factors Reduce Amyloid-Beta Pathology in a Mouse Model of Alzheimer’s Disease. Neurobiol. Aging 2017; 51：83-96
xii、Javed Butler, Stephen E. Epstein, etc. Intravenous Allogeneic Mesenchymal Stem Cells for Non-Ischemic Cardiomopathy: Safety and Efficacy Results of a Phase II-A Randomized Trial. Circulation Research.2016.
xiii、T Harach; N Marungruang, etc. Reduction of Abeta amyloid pathology in APPPS1 transgenic mice in the absence of gut microbiota. Sci Rep 2017; 7：41802
xiv、Ivan Cheng etc. Does timing of transplantation of neural stem cells following spinal cord injury affect outcomes in an animal model J Spine Surg 2017;3(4):567-571
xv、Michael L. Levy, John R. Crawford, Nabil Dib, Michael L, et al. Phase I/II Study of Safety and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Chronic Stroke. Stroke. 2019 Oct;50(10):2835-2841.
Copyright: Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.
